Expanding Access to Long-Acting ART in Europe

In this podcast, Stephane De Wit, MD, PhD, discusses the importance and the challenges of targeting migrant populations for long-acting antiretroviral therapy in Europe—and specifically in Belgium.
Stephane De Wit, MD, PhD
Released: December 19, 2022

In this episode, Stephane De Wit, MD, PhD, discusses the benefits of long-acting antiretroviral therapy (ART) for migrant populations in Europe—and specifically in Belgium. He also addresses some of the challenges of accessing and following up with those populations.

Dr De Wit describes some of the ways that the Belgian healthcare system is set up to improve access to ART. He then explains some of the disease parameters for considering expanding the use of long-acting ART to patients who are not virologically suppressed. Finally, Dr De Wit offers some thoughts about the future of long-acting ART to migrant populations in Belgium.

Information on this Educational Activity

Faculty

Stephane De Wit, MD, PhD

Former Head
Infectious Diseases
Saint Pierre University Hospital
Brussels, Belgium

Stephane De Wit, MD, PhD, has no relevant financial relationships to disclose.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings